Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-71M | $-66M | $-49M | -33.8% | -100.0% | 34.7% |
| 2024 | $1M | $-55M | $-49M | $-45M | -39.4% | - | 16.2% |
| 2023 | $0M | $-48M | $-42M | $-41M | -28.6% | - | 8.3% |
| 2022 | $0M | $-40M | $-39M | $-34M | -21.6% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 72.84 |
| Research And Development | 55.97 |
| Selling General And Administration | 16.87 |
| Total Expenses | 72.84 |
| Operating Income | -72.84 |
| Total Operating Income As Reported | -72.84 |
| EBITDA | -71.37 |
| Normalized EBITDA | -71.37 |
| EBIT | -72.84 |
| Interest Income | 6.40 |
| Interest Expense | - |
| Net Interest Income | 6.40 |
| Other Non Operating Income Expenses | -0.05 |
| Other Income Expense | -0.05 |
| Interest Income Non Operating | 6.40 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 6.40 |
| Pretax Income | -66.49 |
| Tax Provision | - |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -66.49 |
| Net Income From Continuing And Discontinued Operation | -66.49 |
| Net Income From Continuing Operation Net Minority Interest | -66.49 |
| Net Income | -66.49 |
| Net Income Common Stockholders | -66.49 |
| Net Income Including Noncontrolling Interests | -66.49 |
| Normalized Income | -66.49 |
| Diluted NI Availto Com Stockholders | -66.49 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 1.47 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Other Special Charges | - |
| General And Administrative Expense | 16.87 |
| Other Gand A | 16.87 |
| Gain On Sale Of Ppe | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Compass Therapeutics, Inc.this co. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Community Health Systems, Inc. | CYH | $393M | 0.77 | -0.28 | -36.5% | 5.53 |
| TruBridge, Inc. | TBRG | $391M | 89.74 | 2.20 | 2.4% | 12.54 |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Benitec Biopharma Inc. | BNTC | $380M |
| - |
| - |
| - |
| - |
| - |
| -10.01 |
| 3.90 |
| -39.0% |
| -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M | 25.26 | 2.67 | 10.6% | 7.36 |
| CapsoVision, Inc. | CV | $377M | -14.88 | 28.41 | -190.9% | -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Peer Median | - | -3.75 | 1.86 | -37.7% | -3.28 | |